Study: Bevacizumab “Equivalent” to Ranibuzumab for Treating AMD

What’s the difference between bevacizumab (Avastin) and ranibuzumab (Lucentis)? Both are cancer drugs used for the treatment of “wet” age-related macular degeneration (AMD) with similar effects, according to a government study funded by the National Eye Institute.

“At 1 year, bevacizumab and ranibuzumab had equivalent effects on visual acuity when administered according to the same schedule,” researchers conclude in the one-year study, published this spring in the New England Journal of Medicine.

Where the differences lie, the study suggests, is that ranibuzumab is approved by the Food and Drug Administration (FDA) expressly for the purpose of treating neovascular AMD, and bevacizumab is not. And ranibuzumab is $2,000 a dose, and bevacizumab is not. At only $50 a dose, bevacizumab seems like the more favorable choice. Genentech, the company that markets both drugs, disagrees.

Outpatient Surgery has more on this story.

3 Responses to “Study: Bevacizumab “Equivalent” to Ranibuzumab for Treating AMD”

  1. BEVERLY VENIT says:

    What are the long term effects of these drugs. I’v had 2 injections of Avastin for AMD now the doctor wants me to have the third injection with Lucentis. I know there is a big cost difference but the effects are what concern me.
    What is the projected time that you have to take these monthly shots ,or has that not been determined yet.

  2. BEVERLY VENIT says:

    ARE these drugs dangerous.

  3. BEVERLY VENIT says:

    CATT did a Visual Acuity at 2 years and 99% confidencce Intervals and Ranibzumab did better that the Bevacizumab….what do you think??

Leave a Reply

Your email address will not be published. Required fields are marked *